

FORM 51-102F3

Material Change Report

1. Name and Address of Company

Biosign Technologies Inc.
14-3715 Laird Road
Mississauga ON L5L 0A3

2 Date of Material Change

July 29, 2014

3. News Release

The news release attached hereto as Schedule "A" was issued by the Corporation and disseminated via Canada Newswire on July 24, 2014.

4. Summary of Material Change

The Company announced the resignation of a member of the Board of Directors.

5. Full Description of Material Change

The Company announced that Mr. Ron Kelusky has joined the Board, effective July 24, 2014.

With this change, the Board now consists of Dr. Michael Gross (Chairman), Mr. Dennis Rygwalski (Chair of the Audit Committee), Mr. Brian Neill, Mr. Ron Kelusky and Mr. Robert Kaul (Biosign CEO).

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No significant facts remain confidential in, and no information has been omitted from, this report.

8. Executive Officer

For further information please contact Robert Kaul, Chief Executive Officer at (416) 218-9800 x 201.

9. Date of Report

July 29, 2014

SCHEDULE A

Biosign Adds Ron Kelusky to the Board of Directors

TORONTO, July 24, 2014 /CNW/ - **Biosign Technologies Inc. (TSXV: BIO)** ("Biosign" or the "Company") is pleased to announce the appointment of **Ron Kelusky** to the Board. Mr. Kelusky is the President & CEO of Public Services Health & Safety Association of Ontario (PSHSA). PSHSA works with Ontario's 10,000 public and broader public service sector employers and 1.5 million workers, offering consulting, training, resources, plus health & safety products and information to clients in health and community care, education and culture, municipal and provincial government, and public safety and First Nations communities. From 2009-2013 Mr Kelusky was Director General of the Canadian Red Cross, responsible for Ontario operations and all National Health programming, overseeing 4,000 full and part time staff, 6,000 volunteers and an annual operating budget of \$175.0 million. From 2006 - 2009 he was President, Health Division for GestureTek Incorporated; from 2003-2006 he was Chief Operating Officer for March of Dimes Canada; and from 1998-2003 he served as Chief and General Manager for the City of Toronto Emergency Medical Services. Mr. Kelusky has an MBA from Athabasca University.

With this change, the Board now consists of Dr. Michael Gross (Chairman), Mr. Dennis Rygwalski (Chair of the Audit Committee), Mr. Ron Kelusky, Mr. Brian Neill and Mr. Robert Kaul (Biosign CEO).

Mr. Kaul stated: "We are fortunate to be able to welcome Mr. Kelusky to our team. As a very experienced manager, executive & public servant, he brings to us a strong body of knowledge in pertinent fields of health, wellness, homecare and aging-in-place. His advice and counsel will be instrumental to our future as a leading provider of healthcare solutions. The appointment of Mr. Kelusky is a further indication that our restructuring plan is nearing completion, and a strong endorsement of the leadership and direction of the management team."

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's various software solutions, including Clinicserver™ and PencilThat™ offer industry-leading allied health clinic and patient centered care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

%SEDAR: 00014068E

For further information: Biosign Contact Information: Robert Kaul, Chief Executive Officer, Biosign Technologies, Phone: (416) 218-9800 ext. 201, Email: ceo@biosign.com

CO: Biosign Technologies Inc.

CNW 16:01e 24-JUL-14